Review seeks public views on baby sex selection [UK]
By The Guardian,
The Guardian
| 08. 16. 2005
The option for parents to select the sex of their next baby to balance their family is raised in a public consultation document published today.
The government said that its review of the Human Fertilisation and Embryology Act of 1990 will seek views from the public on sex selection for non-medical purposes.
The review will ask whether the practice should be banned - as it is currently - or be allowed for family balancing reasons.
Sex selection is allowed by the Human Fertilisation and Embryology Authority (HFEA) in order to avoid babies being born with disorders such as haemophilia.
But its use for family balancing was opposed by the fertility watchdog after a public consultation.
Now the government has raised the issue again in its wide-ranging consultation on fertility legislation, which has not been updated for 15 years.
The review will also consider, if sex selection was made more widely available, how many children of one gender should a couple already have before they are allowed to use screening techniques to try for a child of another gender.
Sex selection...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...